We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current and future management of chronic spontaneous urticaria and chronic inducible urticaria.
- Authors
Do, Toan T.; Canty, Ethan A.; Joshi, Shyam R.
- Abstract
Background: Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy. Objective: A review of the current literature of standard and novel therapeutics in the management of CU was conducted. Methods: A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials. Results: Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab. Conclusion: Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.
- Subjects
URTICARIA; DUPILUMAB; MEDICAL literature; CLINICAL trials; OMALIZUMAB; LITERATURE reviews
- Publication
Allergy & Asthma Proceedings, 2023, Vol 44, Issue 1, p3
- ISSN
1088-5412
- Publication type
Article
- DOI
10.2500/aap.2023.44.220093